Navigation Links
Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
Date:2/20/2008

SAN DIEGO, Feb. 20 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it completed its previously announced registered direct offering of approximately 9.2 million shares of common stock at a price of $5.34 per share, for gross proceeds of $49.3 million.

"The proceeds from the offering will enable us to continue to advance the clinical development programs for our two products candidates, Acetavance(TM) for the treatment of acute pain and fever, and Omigard(TM) for the prevention of catheter-related infections," stated Ted Schroeder, President and Chief Executive Officer of Cadence. "We believe that we now have sufficient capital to advance these two product candidates through to NDA submissions, currently anticipated in the first half of 2009."

In addition to significant participation from existing investors Domain Associates, Frazier Healthcare Ventures and Versant Ventures, as well as from certain executive officers and directors of Cadence, other investors participating in this financing included, among others, Bay City Capital.

All of the shares of Cadence common stock were issued pursuant to an effective registration statement previously filed with the U.S. Securities and Exchange Commission. The offering and sale of these securities were made only by means of a prospectus supplement and accompanying prospectus. This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
2. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIO Investor Forum
6. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference
7. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
10. Vion Pharmaceuticals to Implement a One-for-Ten Reverse Stock Split
11. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014  Kainos Capital, a firm specializing ... announced that it has acquired the Slim-Fast brand from ... business. Terms of the transaction were not disclosed. ... replacement business that markets ready-to-drink shakes, powders, bars and ... and in the United Kingdom ...
(Date:7/10/2014)... 10, 2014   Ceres, Inc . (Nasdaq: ... announced today financial results for the three months ended ... business. Ceres reported that the company and ... this growing season in Brazil, which concluded in June, ... sorghum evaluation areas for part of the growing season. ...
(Date:7/10/2014)... June 17, 2014 Using microscopic polymer light ... gases, researchers at MIT,s Quantum Photonics Laboratory have ... in the parts-per-billion range. Optical sensors are ideal ... high signal-to-noise ratio, compact, lightweight nature, and immunity ... sensors had been developed before, the MIT team ...
(Date:7/10/2014)... have observed the fractional quantum Hall effect in bilayer ... can be tuned by an electric field. , ... electrons confined to thin sheets are exposed to large ... where thousands of individual electrons behave as a single ... is well established, many details of this collective behavior ...
Breaking Biology Technology:Kainos Capital Acquires Slim-Fast From Unilever 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Swell new sensors 2Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3
... ARI Network Services, Inc., a provider of electronic ... on Wednesday reported increased revenues and record net income for ... for fiscal 2005 were $13.7 million, a 2% increase from ... 67% to $2.1 million or $0.32 per diluted share, from ...
... Third Wave Technologies Inc. has filed suit against ... products, the company announced on Tuesday. The suits were filed ... filed suit against Digene Corp., seeking a court ... virus (HPV) products. , ,On Tuesday, Third Wave filed suit ...
... Barrett and Milwaukee officials on Wednesday announced plans to ... wireless network accessible to all residents. , ,The Milwaukee ... wireless large city in America, built at no cost ... office. , ,"This initiative constitutes a multi-million dollar private ...
Cached Biology Technology:Third Wave files patent suits against Digene, Chiron and Bayer 2Milwaukee announces citywide wireless initiative 2
(Date:7/11/2014)... many fires burning in eastern New South Wales, Australia ... , At 03:35 UTC on July 11 (12:35 p.m. ... passed over eastern New South Wales (NSW), the Moderate ... image of the region and spotted smoke (light brown) ... thermal bands, are outlined in red. , The New ...
(Date:7/11/2014)... creating a new professorship in tissue engineering to ... Molecular Engineering and the Marine Biological Laboratory, supported ... and Eugene Bell Foundation., The Eugene Bell Professorship ... for Molecular Engineering. That endowed chair holder also ... Eugene Bell Center for Regenerative Biology and Tissue ...
(Date:7/11/2014)... Standards and Technology (NIST) need a special tool ... prove that necessity is truly the mother of ... Lorna De Leoz and Stephen Stein, NIST chemists ... is the study of the abundant, often-branched sugar ... and lipids and influence cellular processes, including immunity, ...
Breaking Biology News(10 mins):New professorship in tissue engineering links molecular engineering, marine biology 2
... In an Early Edition publication of The Proceedings of ... week, the researchers demonstrate the "alpha-synuclein dance" the switching ... and an extended helix as the surface that it is ... so directly observed in proteins like alpha-synuclein, which are known ...
... an extremely effective HIV treatment that keeps virus levels ... virus as some HIV always remains dormant in cells. ... approved as a leukemia drug, has now been shown ... candidate to weed out the hidden virus that HAART ...
... 2009 -- Planting soybean on the optimum date produces maximum ... planting date is hard to indentify, because it varies from ... it rains and when it rains. "Planting date ... was introduced into the United States, so there is a ...
Cached Biology News:Scripps research scientists 'watch' as individual alpha-synuclein proteins change shape 2Scripps research scientists 'watch' as individual alpha-synuclein proteins change shape 3No consistent advantage for planting soybean early 2
MOUSE ANTI SIMIAN VIRUS 5 Immunogen: Simian virus 5...
... Dog Serum-Mixed Breed • Dog serum is collected ... one year of age Available Anticoagulants: ... (Na) N-06: K2EDTA N-08: ... N-03: Alsevers N-05: ACD ...
Ready-to-use; 40mg/ml X-Gal and 32mg/ml IPTG...
Whole blood is collected from canines (any breed, either sex), refrigerated within 6 hours, processed within 24 hours and frozen at -20C....
Biology Products: